Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics

References

• Abd TT, Jacobson TA. (2011). Statin-induced myopathy: a review and update. Expert Opin Drug Saf 10:373–87.
   PubMed Web of Science ®Google Scholar
• Abe T, Kakyo M, Tokui T, et al. (1999). Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159–63.
   PubMed Web of Science ®Google Scholar
• Abe T, Unno M, Onogawa T, et al. (2001). LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterol 120:1689–99.
   PubMed Web of Science ®Google Scholar
• Abecasis GR, Auton A, Brooks LD, et al. (2012). An integrated map of genetic variation from 1,092 human genomes. Nature 491:56–65.
   PubMed Web of Science ®Google Scholar
• Auton A, Brooks LD, Durbin RM, et al. (2015). A global reference for human genetic variation. Nature 526:68–74.
   PubMed Web of Science ®Google Scholar
• Baker SD, Verweij J, Cusatis GA, et al. (2009). Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85:155–63.
   PubMed Web of Science ®Google Scholar
• Bauer M, Matsuda A, Wulkersdorfer B, et al. (2018). Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography. Clin Pharmacol Ther 104:139–47.
   PubMed Web of Science ®Google Scholar
• Bednarczyk D. (2010). Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3. Anal Biochem 405:50–8.
   PubMed Web of Science ®Google Scholar
• Bednarczyk D, Boiselle C. (2016). Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III. Xenobiotica 46:457–66.
   PubMed Web of Science ®Google Scholar
• Bernsdorf A, Giessmann T, Modess C, et al. (2006). Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 61:440–50.
   PubMed Web of Science ®Google Scholar
• Bi YA, Costales C, Mathialagan S, et al. (2019). Quantitative contribution of six major transporters to the hepatic uptake of drugs: 'SLC-phenotyping' using primary human hepatocytes. J Pharmacol Exp Ther 370:72–83.
   PubMed Web of Science ®Google Scholar
• Bian J, Jin M, Yue M, et al. (2016). Tryptophan residue located at the middle of putative transmembrane domain 11 is critical for the function of organic anion transporting polypeptide 2B1. Mol Pharm 13:3553–63.
   PubMedGoogle Scholar
• Bins S, van Doorn L, Phelps MA, et al. (2017). Influence of OATP1B1 Function on the disposition of sorafenib-β-D-glucuronide. Clin Transl Sci 10:271–9.
   PubMed Web of Science ®Google Scholar
• Brannstrom M, Nordell P, Bonn B, et al. (2015). Montelukast disposition: no indication of transporter-mediated uptake in OATP2B1 and OATP1B1 expressing HEK293 cells. Pharmaceutics 7:554–64.
   PubMed Web of Science ®Google Scholar
• Brenner S, Riha J, Giessrigl B, et al. (2015). The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells. Int J Oncol 46:324–32.
   PubMed Web of Science ®Google Scholar
• Briz O, Romero MR, Martinez-Becerra P, et al. (2006). OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes? J Biol Chem 281:30326–35.
   PubMed Web of Science ®Google Scholar
• Briz O, Serrano MA, MacIas RI, et al. (2003). Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 371:897–905.
   PubMed Web of Science ®Google Scholar
• Briz O, Serrano MA, Rebollo N, et al. (2002). Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol Pharmacol 61:853–60.
   PubMed Web of Science ®Google Scholar
• Brody JA, Morrison AC, Bis JC, et al. (2017). Analysis commons, a team approach to discovery in a big-data environment for genetic epidemiology. Nat Genet 49:1560–3.
   PubMed Web of Science ®Google Scholar
• Burt HJ, Riedmaier AE, Harwood MD, et al. (2016). Abundance of hepatic transporters in caucasians: a meta-analysis. Drug Metab Dispos 44:1550–61.
   PubMed Web of Science ®Google Scholar
• Chae YJ, Lee KR, Noh CK, et al. (2012). Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population. J Pharm Sci 101:1302–13.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen L, Zhang H, et al. (2018). Interaction of sulfonylureas with liver uptake transporters OATP1B1 and OATP1B3. Basic Clin Pharmacol Toxicol 123:147–54.
   PubMed Web of Science ®Google Scholar
• Choi CI, Lee YJ, Lee HI, et al. (2012). Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. Xenobiotica 42:496–501.
   PubMed Web of Science ®Google Scholar
• Chung JY, Cho JY, Yu KS, et al. (2005). Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78:342–50.
   PubMed Web of Science ®Google Scholar
• Cui Y, Konig J, Leier I, et al. (2001). Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626–30.
   PubMed Web of Science ®Google Scholar
• De Bruyn T, Stieger B, Augustijns PF, Annaert PP. (2016). Clearance prediction of HIV protease inhibitors in man: role of hepatic uptake. J Pharm Sci 105:854–63.
   PubMed Web of Science ®Google Scholar
• de Graaf W, Hausler S, Heger M, et al. (2011). Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol 54:738–45.
   PubMed Web of Science ®Google Scholar
• de Graan AJ, Lancaster CS, Obaidat A, et al. (2012). Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 18:4433–40.
   PubMed Web of Science ®Google Scholar
• de Waart DR, Hausler S, Vlaming ML, et al. (2010). Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein. J Pharmacol Exp Ther 334:78–86.
   PubMed Web of Science ®Google Scholar
• Deng JW, Song IS, Shin HJ, et al. (2008). The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genom 18:424–33.
   PubMed Web of Science ®Google Scholar
• Drenberg CD, Paugh SW, Pounds SB, et al. (2016). Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther 99:651–60.
   PubMed Web of Science ®Google Scholar
• Eley T, Han YH, Huang SP, et al. (2015). Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease. Clin Pharmacol Ther 97:159–66.
   PubMed Web of Science ®Google Scholar
• Fehrenbach T, Cui Y, Faulstich H, Keppler D. (2003). Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol 368:415–20.
   PubMed Web of Science ®Google Scholar
• Fischer WJ, Altheimer S, Cattori V, et al. (2005). Organic anion transporting polypeptides expressed in liver and brain mediate uptake of microcystin. Toxicol Appl Pharmacol 203:257–63.
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Ogawa S, Kojima J. (2005). Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 57:1305–11.
   PubMed Web of Science ®Google Scholar
• Fujita D, Saito Y, Nakanishi T, Tamai I. (2016). Organic anion transporting polypeptide (OATP)2B1 contributes to gastrointestinal toxicity of anticancer drug SN-38, active metabolite of irinotecan hydrochloride. Drug Metab Dispos 44:1–7.
   PubMed Web of Science ®Google Scholar
• Fujita K, Sugiura T, Okumura H, et al. (2014). Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res 31:204–15.
   PubMed Web of Science ®Google Scholar
• Furihata T, Satoh N, Ohishi T, et al. (2009). Functional analysis of a mutation in the SLCO1B1 gene (c.1628T > G) identified in a Japanese patient with pravastatin-induced myopathy. Pharmacogenomics J 9:185–93.
   PubMed Web of Science ®Google Scholar
• Glaeser H, Bujok K, Schmidt I, et al. (2014). Organic anion transporting polypeptides and organic cation transporter 1 contribute to the cellular uptake of the flavonoid quercetin. Naunyn Schmiedebergs Arch Pharmacol 387:883–91.
   PubMed Web of Science ®Google Scholar
• Grube M, Kock K, Karner S, et al. (2006a). Modification of OATP2B1-mediated transport by steroid hormones. Mol Pharmacol 70:1735–41.
   PubMed Web of Science ®Google Scholar
• Grube M, Kock K, Oswald S, et al. (2006b). Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 80:607–20.
   PubMed Web of Science ®Google Scholar
• Gui C, Hagenbuch B. (2008). Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport. Biochem 47:9090–7.
   PubMed Web of Science ®Google Scholar
• Gui C, Hagenbuch B. (2009). Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1. Protein Sci 18: 2298–306.
   PubMed Web of Science ®Google Scholar
• Gui C, Miao Y, Thompson L, et al. (2008). Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 584:57–65.
   PubMed Web of Science ®Google Scholar
• Gui C, Obaidat A, Chaguturu R, Hagenbuch B. (2010). Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 4:1–8.
   PubMedGoogle Scholar
• Hagenbuch B, Gui C. (2008). Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778–801.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. (2003). The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1–18.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. (2004). Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–65.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Stieger B. (2013). The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med 34:396–412.
   PubMed Web of Science ®Google Scholar
• Hamada A, Sissung T, Price DK, et al. (2008). Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 14:3312–8.
   PubMed Web of Science ®Google Scholar
• Han LW, Gao C, Zhang Y, et al. (2018). Transport of bupropion and its metabolites by the model CHO and HEK293 cell lines. Drug Metab Lett 13:25–36.
   Google Scholar
• Hartkoorn RC, Kwan WS, Shallcross V, et al. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genom 20:112–20.
   PubMed Web of Science ®Google Scholar
• Hays A, Apte U, Hagenbuch B. (2013). Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomas. Pharm Res 30:2260–9.
   PubMed Web of Science ®Google Scholar
• He KY, Li X, Kelly TN, et al. (2019). Leveraging linkage evidence to identify low-frequency and rare variants on 16p13 associated with blood pressure using TOPMed whole genome sequencing data. Hum Genet 138:199–210.
   PubMed Web of Science ®Google Scholar
• Hediger MA, Romero MF, Peng JB, et al. (2004). The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch 447:465–8.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139–46.
   PubMed Web of Science ®Google Scholar
• Ho RH, Choi L, Lee W, et al. (2007). Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genom 17:647–56.
   PubMed Web of Science ®Google Scholar
• Ho RH, Tirona RG, Leake BF, et al. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterol 130:1793–806.
   PubMed Web of Science ®Google Scholar
• Hsiang B, Zhu Y, Wang Z, et al. (1999). A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161–8.
   PubMed Web of Science ®Google Scholar
• Hu S, Franke RM, Filipski KK, et al. (2008). Interaction of imatinib with human organic ion carriers. Clin Cancer Res 14:3141–8.
   PubMed Web of Science ®Google Scholar
• Hu M, Mak VW, Yin OQ, et al. (2013). Effects of grapefruit juice and SLCO1B1 388A > G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab Pharmacok 28:104–8.
   PubMed Web of Science ®Google Scholar
• Hua WJ, Hua WX, Nan FY, et al. (2014). The influence of herbal medicine ursolic acid on the uptake of rosuvastatin mediated by OATP1B1*1a and *5. Eur J Drug Metab Pharmacok 39:221–30.
   PubMed Web of Science ®Google Scholar
• Ieiri I, Nishimura C, Maeda K, et al. (2011). Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genom 21:495–505.
   PubMed Web of Science ®Google Scholar
• Iida A, Saito S, Sekine A, et al. (2001). Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH: ubiquinone oxidoreductase flavoproteins. J Hum Genet 46:668–83.
   PubMed Web of Science ®Google Scholar
• Imanaga J, Kotegawa T, Imai H, et al. (2011). The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genom 21:84–93.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Maeda K, Kishimoto W, et al. (2006). Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109–15.
   PubMed Web of Science ®Google Scholar
• Ismair MG, Stieger B, Cattori V, et al. (2001). Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterol 121:1185–90.
   PubMed Web of Science ®Google Scholar
• Izumi S, Nozaki Y, Komori T, et al. (2016). Investigation of fluorescein derivatives as substrates of organic anion transporting polypeptide (OATP) 1B1 to develop sensitive fluorescence-based OATP1B1 inhibition assays. Mol Pharm 13:438–48.
   PubMed Web of Science ®Google Scholar
• Izumi S, Nozaki Y, Kusuhara H, et al. (2018). Relative activity factor (RAF)-based scaling of uptake clearance mediated by organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes. Mol Pharm 15:2277–88.
   PubMed Web of Science ®Google Scholar
• Izumi S, Nozaki Y, Maeda K, et al. (2015). Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos 43:235–47.
   PubMed Web of Science ®Google Scholar
• Jacquemin E, Hagenbuch B, Stieger B, et al. (1994). Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci USA 91:133–7.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. (2008). Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genom 18:937–42.
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, et al. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genom 15:513–22.
   PubMed Web of Science ®Google Scholar
• Karczewski KJ, Francioli LC, Tiao G, et al. (2019). Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv. https://doi.org/10.1101/531210
   Google Scholar
• Karlgren M, Vildhede A, Norinder U, et al. (2012). Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 55:4740–63.
   PubMed Web of Science ®Google Scholar
• Kato K, Shirasaka Y, Kuraoka E, et al. (2010). Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport. Mol Pharm 7:1747–56.
   PubMed Web of Science ®Google Scholar
• Katz DA, Carr R, Grimm DR, et al. (2006). Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther 79:186–96.
   PubMed Web of Science ®Google Scholar
• Khurana V, Minocha M, Pal D, Mitra AK. (2014). Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. Drug Metab Drug Interact 29:179–90.
   PubMedGoogle Scholar
• Kim KA, Lee HM, Joo HJ, et al. (2013). Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol 53:1186–93.
   PubMed Web of Science ®Google Scholar
• Kim TE, Shin D, Gu N, et al. (2017). The effect of genetic polymorphisms in SLCO2B1 on the lipid-lowering efficacy of rosuvastatin in healthy adults with elevated low-density lipoprotein. Basic Clin Pharmacol Toxicol 121:195–201.
   PubMed Web of Science ®Google Scholar
• Kimoto E, Mathialagan S, Tylaska L, et al. (2018). Organic anion transporter 2-mediated hepatic uptake contributes to the clearance of high-permeability-low-molecular-weight acid and Zwitterion drugs: evaluation using 25 drugs. J Pharmacol Exp Ther 367:322–34.
   PubMed Web of Science ®Google Scholar
• Kimoto E, Yoshida K, Balogh LM, et al. (2012). Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm 9:3535–42.
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Kubo M, et al. (2008). Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 99:967–72.
   PubMed Web of Science ®Google Scholar
• Kohlrausch FB, de Cassia Estrela R, Barroso PF, Suarez-Kurtz G. (2010). The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol 69:95–8.
   PubMed Web of Science ®Google Scholar
• Komatsu M, Furukawa T, Ikeda R, et al. (2007). Involvement of mitogen-activated protein kinase signaling pathways in microcystin-LR-induced apoptosis after its selective uptake mediated by OATP1B1 and OATP1B3. Toxicol Sci 97:407–16.
   PubMed Web of Science ®Google Scholar
• Kondo A, Narumi K, Ogura J, et al. (2017). Organic anion-transporting polypeptide (OATP) 2B1 contributes to the cellular uptake of theaflavin. Drug Metab Pharmacok 32:145–50.
   PubMed Web of Science ®Google Scholar
• Konig J, Cui Y, Nies AT, Keppler D. (2000a). Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275:23161–8.
   PubMed Web of Science ®Google Scholar
• Konig J, Cui Y, Nies AT, Keppler D. (2000b). A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastr L 278:G156–164.
   PubMed Web of Science ®Google Scholar
• Konig J, Glaeser H, Keiser M, et al. (2011). Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos 39:1097–102.
   PubMed Web of Science ®Google Scholar
• Kopplow K, Letschert K, Konig J, et al. (2005). Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 68:1031–8.
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Ismair MG, Stieger B, et al. (2001). Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterol 120:525–33.
   PubMed Web of Science ®Google Scholar
• Lancaster CS, Bruun GH, Peer CJ, et al. (2012). OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther 92:642–50.
   PubMed Web of Science ®Google Scholar
• Lancaster CS, Sprowl JA, Walker AL, et al. (2013). Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther 12:1537–44.
   PubMed Web of Science ®Google Scholar
• Lau YY, Huang Y, Frassetto L, Benet LZ. (2007). Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204.
   PubMed Web of Science ®Google Scholar
• Lee HH, Leake BF, Teft W, et al. (2015). Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance. Mol Cancer Ther 14:994–1003.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee MG, Lim LA, et al. (2010). Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 48:36–45.
   PubMed Web of Science ®Google Scholar
• Lek M, Karczewski KJ, Minikel EV, et al. (2016). Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–91.
   PubMed Web of Science ®Google Scholar
• Letschert K, Faulstich H, Keller D, Keppler D. (2006). Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 91:140–9.
   PubMed Web of Science ®Google Scholar
• Letschert K, Keppler D, Konig J. (2004). Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14:441–52.
   PubMedGoogle Scholar
• Li J, Wang XR, Zhai XW, et al. (2015). Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia. Int J Clin Exp Med 8:6109–13.
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, et al. (2008). SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 359:789–99.
   PubMed Web of Science ®Google Scholar
• Liu L, Cui Y, Chung AY, et al. (2006). Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther 318:395–402.
   PubMed Web of Science ®Google Scholar
• Liu SG, Gao C, Zhang RD, et al. (2017). Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget 8:37761–72.
   PubMedGoogle Scholar
• Maeda K, Ieiri I, Yasuda K, et al. (2006a). Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79:427–39.
   PubMed Web of Science ®Google Scholar
• Maeda K, Kambara M, Tian Y, et al. (2006b). Uptake of ursodeoxycholate and its conjugates by human hepatocytes: role of Na(+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and oatp1B3 (OATP8). Mol Pharm 3:70–7.
   PubMedGoogle Scholar
• Martinez D, Muhrez K, Woillard JB, et al. (2018). Endogenous metabolites-mediated communication between OAT1/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity. Clin Pharmacol Ther 104:687–98.
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Ishiguro N, et al. (2008). Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36:663–9.
   PubMed Web of Science ®Google Scholar
• Meier-Abt F, Faulstich H, Hagenbuch B. (2004). Identification of phalloidin uptake systems of rat and human liver. Biochim Biophys Acta 1664:64–9.
   PubMed Web of Science ®Google Scholar
• Meyer Zu Schwabedissen HE, Boettcher K, Steiner T, et al. (2014). OATP1B3 is expressed in pancreatic β-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide . Diabetes 63:775–84.
   PubMed Web of Science ®Google Scholar
• Ming X, Knight BM, Thakker DR. (2011). Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol Pharm 8:1677–86.
   PubMed Web of Science ®Google Scholar
• Mori D, Kashihara Y, Yoshikado T, et al. (2019). Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacok 34:78–86.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Oishi T, Ueda S, et al. (2004). A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacok 19:453–5.
   PubMedGoogle Scholar
• Morio H, Sun Y, Harada M, et al. (2018). Cancer-type OATP1B3 mRNA in extracellular vesicles as a promising candidate for a serum-based colorectal cancer biomarker. Biol Pharm Bull 41:445–9.
   PubMed Web of Science ®Google Scholar
• Mougey EB, Feng H, Castro M, et al. (2009). Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genom 19:129–38.
   PubMed Web of Science ®Google Scholar
• Mougey EB, Lang JE, Wen X, Lima JJ. (2011). Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol 51:751–60.
   PubMed Web of Science ®Google Scholar
• Mwinyi J, Johne A, Bauer S, et al. (2004). Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75:415–21.
   PubMed Web of Science ®Google Scholar
• Nakagomi-Hagihara R, Nakai D, Kawai K, et al. (2006). OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos 34:862–9.
   PubMed Web of Science ®Google Scholar
• Nakai D, Nakagomi R, Furuta Y, et al. (2001). Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861–7.
   PubMed Web of Science ®Google Scholar
• Nakakariya M, Shimada T, Irokawa M, et al. (2008). Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. Drug Metab Pharmacok 23:347–55.
   PubMed Web of Science ®Google Scholar
• Natarajan P, Peloso GM, Zekavat SM, et al. (2018). Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. Nat Commun 9:3391.
   PubMed Web of Science ®Google Scholar
• Ni W, Ji J, Dai Z, et al. (2010). Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One 5:e13792.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Kajosaari LI, et al. (2005a). Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468–78.
   PubMed Web of Science ®Google Scholar
• Niemi M, Kivisto KT, Hofmann U, et al. (2005b). Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602–4.
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T, et al. (2004). High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429–40.
   PubMedGoogle Scholar
• Nishizato Y, Ieiri I, Suzuki H, et al. (2003). Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554–65.
   PubMed Web of Science ®Google Scholar
• Noe J, Portmann R, Brun ME, Funk C. (2007). Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308–14.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Imai K, Nezu J, et al. (2004a). Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308:438–45.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Minami H, Sugiura S, et al. (2005a). Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434–9.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Nakajima M, Tamai I, et al. (2002). Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804–13.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Sugiura S, Nakajima M, et al. (2004b). Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 32:291–4.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Suzuki M, Yabuuchi H, et al. (2005b). Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharm Res 22:1634–41.
   PubMed Web of Science ®Google Scholar
• Obaidat A, Roth M, Hagenbuch B. (2012). The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 52:135–51.
   PubMed Web of Science ®Google Scholar
• Oostendorp RL, van de Steeg E, van der Kruijssen CM, et al. (2009). Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos 37:917–23.
   PubMed Web of Science ®Google Scholar
• Oshida K, Shimamura M, Seya K, et al. (2017). Identification of transporters involved in beraprost sodium transport in vitro. Eur J Drug Metab Ph 42:117–28.
   PubMed Web of Science ®Google Scholar
• Oswald S, Konig J, Lutjohann D, et al. (2008). Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genom 18:559–68.
   PubMed Web of Science ®Google Scholar
• Park HS, Lim SM, Shin HJ, et al. (2016). Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Pharmacogenet Genom 26:116–25.
   PubMed Web of Science ®Google Scholar
• Parvez MM, Shin HJ, Jung JA, Shin JG. (2017). Evaluation of para-aminosalicylic acid as a substrate of multiple solute carrier uptake transporters and possible drug interactions with nonsteroidal anti-inflammatory drugs in vitro. Antimicrob Agents Chemother 61:e02392–16. 5.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. (2007). Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726–33.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. (2006). SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genom 16:873–9.
   PubMed Web of Science ®Google Scholar
• Patik I, Kovacsics D, Nemet O, et al. (2015). Functional expression of the 11 human Organic Anion Transporting Polypeptides in insect cells reveals that sodium fluorescein is a general OATP substrate. Biochem Pharmacol 98:649–58.
   PubMed Web of Science ®Google Scholar
• Pei Q, Liu JY, Yin JY, et al. (2018). Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population. Eur J Clin Pharmacol 74:1021–8.
   PubMed Web of Science ®Google Scholar
• Peng KW, Bacon J, Zheng M, et al. (2015). Ethnic variability in the expression of hepatic drug transporters: absolute quantification by an optimized targeted quantitative proteomic approach. Drug Metab Dispos 43:1045–55.
   PubMed Web of Science ®Google Scholar
• Picard N, Yee SW, Woillard JB, et al. (2010). The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 87:100–8.
   PubMed Web of Science ®Google Scholar
• Pizzagalli F, Hagenbuch B, Stieger B, et al. (2002). Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 16:2283–96.
   PubMed Web of Science ®Google Scholar
• Pizzagalli F, Varga Z, Huber RD, et al. (2003). Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab 88:3902–12.
   PubMed Web of Science ®Google Scholar
• Pond SM, Tozer TN. (1984). First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet 9:1–25.
   PubMed Web of Science ®Google Scholar
• Pressler H, Sissung TM, Venzon D, et al. (2011). Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One 6:e20372.
   PubMed Web of Science ®Google Scholar
• Radtke S, Zolk O, Renner B, et al. (2013). Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121:5145–53.
   PubMed Web of Science ®Google Scholar
• Ramsden D, Tweedie DJ, Chan TS, et al. (2014). Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac. Drug Metab Dispos 42:394–406.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Bruun GH, Yang W, et al. (2012). Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 22:1–8.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Panetta JC, Smith C, et al. (2013). Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 121:898–904.
   PubMed Web of Science ®Google Scholar
• Riha J, Brenner S, Bohmdorfer M, et al. (2014). Resveratrol and its major sulfated conjugates are substrates of organic anion transporting polypeptides (OATPs): impact on growth of ZR-75-1 breast cancer cells. Mol Nutr Food Res 58:1830–42.
   PubMed Web of Science ®Google Scholar
• Roth M, Obaidat A, Hagenbuch B. (2012). OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165:1260–87.
   PubMed Web of Science ®Google Scholar
• Roth M, Timmermann BN, Hagenbuch B. (2011). Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos 39:920–6.
   PubMed Web of Science ®Google Scholar
• Sandhu P, Lee W, Xu X, et al. (2005). Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 33:676–82.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Suzuki H, Ito K, et al. (2002). Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem 277:6497–503.
   PubMed Web of Science ®Google Scholar
• Satoh H, Yamashita F, Tsujimoto M, et al. (2005). Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 33:518–23.
   PubMed Web of Science ®Google Scholar
• Schafer AM, Bock T, Meyer Zu Schwabedissen HE. (2018). Establishment and validation of competitive counterflow as a method to detect substrates of the organic anion transporting polypeptide 2B1. Mol Pharm 15:5501–13.
   PubMedGoogle Scholar
• Schneck DW, Birmingham BK, Zalikowski JA, et al. (2004). The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455–63.
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, et al. (2011). Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genom 21:103–14.
   PubMed Web of Science ®Google Scholar
• Scialis RJ, Manautou JE. (2016). Elucidation of the mechanisms through which the reactive metabolite diclofenac acyl glucuronide can mediate toxicity. J Pharmacol Exp Ther 357:167–76.
   PubMed Web of Science ®Google Scholar
• Seithel A, Eberl S, Singer K, et al. (2007). The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 35:779–86.
   PubMed Web of Science ®Google Scholar
• Shen H, Chen W, Drexler DM, et al. (2017). Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects. Drug Metab Dispos 45:908–19.
   PubMed Web of Science ®Google Scholar
• Shen H, Dai J, Liu T, et al. (2016). Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species. J Pharmacol Exp Ther 357:382–93.
   PubMed Web of Science ®Google Scholar
• Shen H, Yang Z, Mintier G, et al. (2013). Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation. J Pharmacol Exp Ther 344:673–85.
   PubMed Web of Science ®Google Scholar
• Sherry ST, Ward MH, Kholodov M, et al. (2001). dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308–11.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fuse K, Okudaira K, et al. (2005). Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33: 1477–81.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Itoh T, Sato H, et al. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304: 610–6.
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD, et al. (2004). Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167–77.
   PubMed Web of Science ®Google Scholar
• Smith NF, Acharya MR, Desai N, et al. (2005). Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4:815–8.
   PubMed Web of Science ®Google Scholar
• Smith NF, Marsh S, Scott-Horton TJ, et al. (2007). Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 81:76–82.
   PubMed Web of Science ®Google Scholar
• Suga T, Yamaguchi H, Sato T, et al. (2017). Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1 and OATP1B3. PLoS One 12:e0169719.
   PubMed Web of Science ®Google Scholar
• Sun P, Wang C, Liu Q, et al. (2014). OATP and MRP2-mediated hepatic uptake and biliary excretion of eprosartan in rat and human. Pharmacol Rep 66:311–9.
   PubMed Web of Science ®Google Scholar
• Takehara I, Terashima H, Nakayama T, et al. (2017). Investigation of glycochenodeoxycholate sulfate and chenodeoxycholate glucuronide as surrogate endogenous probes for drug interaction studies of OATP1B1 and OATP1B3 in healthy Japanese volunteers. Pharm Res 34:1601–14.
   PubMed Web of Science ®Google Scholar
• Tamai I, Nakanishi T. (2013). OATP transporter-mediated drug absorption and interaction. Curr Opin Pharmacol 13:859–63.
   PubMed Web of Science ®Google Scholar
• Tamai I, Nezu J, Uchino H, et al. (2000). Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273: 251–60.
   PubMed Web of Science ®Google Scholar
• Tamai I, Nozawa T, Koshida M, et al. (2001). Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 18:1262–9.
   PubMed Web of Science ®Google Scholar
• Tapaninen T, Karonen T, Backman JT, et al. (2013). SLCO2B1 c.935G > A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Pharmacogenet Genom 23:19–24.
   PubMed Web of Science ®Google Scholar
• Tennessen JA, Bigham AW, O’Connor TD, et al. (2012). Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337:64–9.
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Merino G, Kim RB. (2001). Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669–75.
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Wolkoff AW, Kim RB. (2003). Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223–8.
   PubMed Web of Science ®Google Scholar
• Treiber A, Schneiter R, Hausler S, Stieger B. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35:1400–7.
   PubMed Web of Science ®Google Scholar
• Trevino LR, Shimasaki N, Yang W, et al. (2009). Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 27:5972–8.
   PubMed Web of Science ®Google Scholar
• Tsuda-Tsukimoto M, Maeda T, Iwanaga T, et al. (2006). Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharm Res 23:2646–56.
   PubMed Web of Science ®Google Scholar
• Tsujimoto M, Dan Y, Hirata S, et al. (2008). Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure. Drug Metab Pharmacok 23:406–11.
   PubMed Web of Science ®Google Scholar
• van de Steeg E, Stranecky V, Hartmannova H, et al. (2012). Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122:519–28.
   PubMed Web of Science ®Google Scholar
• Varma MV, Scialis RJ, Lin J, et al. (2014). Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS J 16:736–48.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Van Montfoort J, Ha HR, et al. (2002). Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164–72.
   PubMed Web of Science ®Google Scholar
• Voora D, Shah SH, Spasojevic I, et al. (2009). The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54:1609–16.
   PubMed Web of Science ®Google Scholar
• Wang P, Hata S, Xiao Y, et al. (2008). Topological assessment of oatp1a1: a 12-transmembrane domain integral membrane protein with three N-linked carbohydrate chains. Am J Physiol Gastr L 294:G1052–1059.
   PubMed Web of Science ®Google Scholar
• Wang M, Lu J, Li J, et al. (2014). Steviol glucuronidation and its potential interaction with UDP-glucuronosyltransferase 2B7 substrates. Food Chem Toxicol 64:135–43.
   PubMed Web of Science ®Google Scholar
• Wen F, Shi M, Bian J, et al. (2016). Identification of natural products as modulators of OATP2B1 using LC-MS/MS to quantify OATP-mediated uptake. Pharm Biol 54:293–302.
   PubMed Web of Science ®Google Scholar
• Wen J, Xiong Y. (2010). OATP1B1 388A > G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther 35:99–104.
   PubMed Web of Science ®Google Scholar
• Xiang X, Jada SR, Li HH, et al. (2006). Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genom 16:683–91.
   PubMed Web of Science ®Google Scholar
• Yamada A, Maeda K, Ishiguro N, et al. (2011). The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genom 21:523–30.
   PubMed Web of Science ®Google Scholar
• Yamada A, Maeda K, Kamiyama E, et al. (2007). Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 35:2166–76.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Kobayashi M, Okada M, et al. (2008). Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 260:163–9.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Okada M, Akitaya S, et al. (2006). Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res 47:1196–202.
   PubMed Web of Science ®Google Scholar
• Yamakawa Y, Hamada A, Nakashima R, et al. (2011). Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit 33:244–50.
   PubMed Web of Science ®Google Scholar
• Yamashiro W, Maeda K, Hirouchi M, et al. (2006). Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247–54.
   PubMed Web of Science ®Google Scholar
• Yang F, Liu L, Chen L, et al. (2018a). OATP1B3 (699G > A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide. Sci Rep 8:18063.
   PubMed Web of Science ®Google Scholar
• Yang M, Xie W, Mostaghel E, et al. (2011). SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 29:2565–73.
   PubMed Web of Science ®Google Scholar
• Yang F, Xiong X, Liu Y, et al. (2018b). CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide. Sci Rep 8:10994.
   PubMed Web of Science ®Google Scholar
• Yee SW, Giacomini MM, Hsueh CH, et al. (2016). Metabolomic and genome-wide association studies reveal potential endogenous biomarkers for OATP1B1. Clin Pharmacol Ther 100:524–36.
   PubMed Web of Science ®Google Scholar
• Yee SW, Giacomini MM, Shen H, et al. (2019). Organic anion transporter polypeptide 1B1 polymorphism modulates the extent of drug-drug interaction and associated biomarker levels in healthy volunteers. Clin Transl Sci. [Epub ahead of print]. doi:10.1111/cts.12625
   Web of Science ®Google Scholar
• Zhang Y, Han YH, Putluru SP, et al. (2016). Diclofenac and its acyl glucuronide: determination of in vivo exposure in human subjects and characterization as human drug transporter substrates in vitro. Drug Metab Dispos 44:320–8.
   PubMed Web of Science ®Google Scholar
• Zhang W, He YJ, Han CT, et al. (2006). Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 62:567–72.
   PubMed Web of Science ®Google Scholar
• Zhang A, Wang C, Liu Q, et al. (2013). Involvement of organic anion-transporting polypeptides in the hepatic uptake of dioscin in rats and humans. Drug Metab Dispos 41:994–1003.
   PubMed Web of Science ®Google Scholar
• Zhao W, Zitzow JD, Weaver Y, et al. (2017). Organic anion transporting polypeptides contribute to the disposition of perfluoroalkyl acids in humans and rats. Toxicol Sci 156:84–95.
   PubMed Web of Science ®Google Scholar
• Zimmerman EI, Hu S, Roberts JL, et al. (2013). Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 19:1458–66.
   PubMed Web of Science ®Google Scholar